Benzodiazepine Drugs Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Alprazolam, Diazepam, Lorazepam, Clonazepam, and Others); By Dosage Form; By Time of Action, By Application, By Region; Segment Forecast, 2024- 2032
- Published Date:Feb-2024
- Pages: 118
- Format: PDF
- Report ID: PM4435
- Base Year: 2023
- Historical Data: 2019 – 2022
Report Outlook
Benzodiazepine drugs market size was valued at USD 3,037.42 million in 2023. The market is anticipated to grow from USD 3,144.03 million in 2024 to USD 4,201.27 million by 2032, exhibiting the CAGR of 3.7% during the forecast period.
Market Overview
The number of people suffering from medical conditions, including anxiety, muscular spasms, and insomnia, is rising, which is driving the demand for benzodiazepines. Moreover, the increasing prevalence of seizures and the growing awareness regarding their early treatment owing to the possibility of various risks boost the market growth. Furthermore, factors such as workplace situations, financial instability, relationship issues, and health problems increase stress levels among the adult population. Thus, an increase in stress levels leading to mental disorders will positively impact the benzodiazepine drug market expansion in the coming years.
For instance, according to the data from The Household Pulse Survey conducted by the U.S. Census Bureau, in 2023, roughly 32.3% of all individuals reported having symptoms of depression and anxiety. The age of nearly half of these adults was 18 to 24.
Benzodiazepine drugs are majorly being selected as the preferred treatment option over other psychoactive medications, which has propelled the benzodiazepine market growth over the past decade. Moreover, the market is also driven by an increase in the use of generic medications and a higher prescription rate for benzodiazepines over its alternatives. Furthermore, the emergence of new and effective medications for seizures, coupled with the rising number of product approvals by regulatory bodies, is expected to fuel the benzodiazepine drugs market size in the projected years.
To Understand More About this Research: Request a Free Sample Report
However, the growing concern associated with the misuse, overdose, and abuse of benzodiazepines can hamper the market growth in the upcoming years. Moreover, the side effects associated with the use of benzodiazepines, such as drowsiness, memory problems, muscle weakness, nausea, unsteadiness, and constipation, will limit the market growth during the forecast period. Furthermore, product recalls due to safety issues are expected to restrain the benzodiazepine drug market growth during the forecast timeframe.
Growth Factors
Increasing Incidence of anxiety and related mental health conditions will drive the market growth
Benzodiazepines are mainly used for the treatment of medical conditions such as anxiety, insomnia, and sleep disorders. Economic pressure, changing lifestyles, urbanization, the consequences of COVID-19, and modern culture are the main causes that increase the incidence rate of mental health problems. For instance, according to a research study conducted by The RAND Corporation for 15 countries, 1 in 12 adults has chronic insomnia. Patients who have insomnia are often associated with workplace-related errors and poor quality of life. Hence, in order to minimize the consequences associated with chronic insomnia, most of the patients are focusing on medical treatment, which ultimately increases the benzodiazepine drug market revenue.
Growing research & development activities for new product development will propel the market
The benzodiazepine drugs effectively treat severe mental health problems, owing to which they have become increasingly popular among healthcare practitioners. This has also encouraged the industry players to increase the research and development activities for the production of benzodiazepine drugs. For instance, STACCATO alprazolam, a benzodiazepine drug from UCB S.A., is currently in Phase 3 of clinical trials. Moreover, the increasing focus of manufacturers to develop and launch benzodiazepines in routes of administration other than oral route is expected to contribute to the benzodiazepine drugs market growth.
Restraining Factors
Risks and side effects associated with benzodiazepine drugs is expected to limit the market growth
Along with the abuse and addiction of benzodiazepine, it also poses some major risks, such as cognitive impairment, motor vehicle crashes, and hip fractures. Patients who are exposed to the long-term use of benzodiazepine are likely to be the victims of these serious risks. Moreover, an increased risk of miscarriage owing to the use of benzodiazepine drugs is expected to hamper the market growth in the coming years. For instance, according to a research study published in JAMA Psychiatry in December 2023, out of the 30,67,122 (3.1 million) pregnancies, 136,134 pregnancies resulted in miscarriage. Such risks associated with the use of benzodiazepine will restrain the market growth in the upcoming years.
Report Segmentation
The market is primarily segmented based on drug type, dosage form, route of administration, time of action, application, distribution channel, and region.
|
By Drug Type |
By Dosage Form |
By Route of Administration |
By Time of Action |
By Application |
By Distribution Channel |
By Region |
|
|
|
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Drug Type Insights
Alprazolam segment dominated the market in 2023
Based on drug type, the Alprazolam segment accounted for the largest market share in 2023. Factors such as the increasing number of prescriptions and the presence of a large patient pool suffering from anxiety and panic disorders are the key contributors to the segmental growth. For instance, according to the data published by the World Health Organization (WHO) in February 2023, epilepsy affects over 50 million individuals worldwide, making it one of the most prevalent neurological conditions. Thus, patients requiring treatment for epilepsy will contribute to the segmental growth, thereby spurring the growth of the benzodiazepine drugs market industry.
By Dosage Form Insights
The injection segment is expected to register significant CAGR in the projected years
The injection segment is projected to witness considerable growth during the forecast timeframe. The increasing need for alcohol withdrawal and the rising use of benzodiazepine as an adjunct for the relief of skeletal muscle spasms and status epilepticus are expected to fuel segmental growth during the forecast period. Moreover, the benefits associated with injectable benzodiazepine over other routes of administration are stimulating the market players to launch new products. For instance, in May 2023, Hikma Pharmaceuticals PLC announced the introduction of Diazepam Injection, USP, in a 50mg/10mL dose, which is used for the management of anxiety disorders. Such product launches will boost the segmental growth in the coming years.
By Time of Action Insights
The ultra-short acting segment is expected to witness significant growth in the future
The ultra-short-acting segment is expected to emerge as the most promising segment during the forecast period. Growing demand for ultra-short-acting benzodiazepines owing to their pharmacokinetic activity and less chances of the development of drug dependency is expected to contribute to segmental growth. Moreover, the increasing need for benzodiazepines as a sedative and anesthetic for surgical procedures will also drive segmental growth. For instance, in August 2023, PAION launched Byfavo (remimazolam), an ultra-short-acting intravenous benzodiazepine in the Netherlands. This product can prevent hemodynamic instability, thereby assisting patients requiring general anesthesia before surgeries.
By Application Insights
The anxiety disorders segment accounted for the largest share
The anxiety disorders segment held the largest benzodiazepine drugs market share in 2023. The segmental share is attributed to the increasing incidence of anxiety disorders arising due to factors such as social isolation, childhood trauma, negative life events, societal pressure, and financial status. For instance, according to the Mental Health Foundation, in 2022–2023, an average of 29.9% of men and 37.1% of women in the UK reported having high levels of anxiety. Moreover, the growing number of patients suffering from social anxiety disorder, panic disorder, and agoraphobia also contributes to the segmental share.
Regional Insights
North America region dominated the benzodiazepine drugs market industry
North America emerged as the largest market in 2023. A large patient pool suffering from numerous mental problems is a primary driver for the dominance of this region. For instance, as per the American Sleep Association (ASA), in 2021, 50 to 70 Mn adults in the U.S. were affected by a sleep disorder. Moreover, the fast-paced nature of modern life, financial strains, and the aftermath of the COVID-19 pandemic are some of the factors that have increased the incidences of anxiety disorders. Such factors leading to anxiety disorders are stimulating the manufacturers to increase research and development activities, thereby generating demand for benzodiazepine in this region.
Asia Pacific's benzodiazepine drugs market trends is anticipated to expand at the highest CAGR during the forecast period. Factors such as fear of the future, inadequate sleep, workplace environment, relationship troubles, financial instability, and stress about goal achievement have become the major causes affecting stress levels among the Indian population. For instance, according to the GOQii India Fit Report 22-23's Stress & Mental Health Study conducted in around 10,000+ Indians, around 26% of the Indians are stressed due to their current work situation. In such people with high levels of stress, benzodiazepines alter the activity of the neurons that trigger stress and anxiety reactions. This increases the demand for benzodiazepine drugs in the region.
Key Market Players & Competitive Insights
Research & development activities are driving the competition in the market
The benzodiazepine drugs market competition is consolidated owing to the strong positions of the companies. The competitive environment in the market is owing to the strategic initiatives including acquisitions, new product development, and research & development activities. For instance, in 2022, Polyrizon Ltd. announced its plans to conduct feasibility study for the benzodiazepine product candidates using the Trap and Target (T&T) technology. Based on the feasibility study, the company will identify two or three leading candidates to proceed to conduct preclinical and clinical studies.
Some of the major players operating in the global market include:
- Amneal Pharmaceuticals LLC (U.S.)
- Apotex Inc. (Canada)
- Aurobindo Pharma (India)
- Bausch Health Companies Inc. (Canada)
- Genentech, Inc. (U.S.)
- H. Lundbeck A/S (Denmark)
- Hikma Pharmaceuticals PLC (UK)
- Pfizer Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Viatris (U.S.)
Recent Developments in the Industry
- In September 2023, Aquestive Therapeutics has received FDA approval of the NDA for its Libervant Buccal Film in the Paediatric Patients between 2-5 years of age.
Report Coverage
The benzodiazepine drugs market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, drug type, dosage form, route of administration, time of action, application, distribution channel, and their futuristic growth opportunities.
Benzodiazepine Drugs Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 3,144.03 million |
|
Revenue forecast in 2032 |
USD 4,201.27 million |
|
CAGR |
3.7% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD million and CAGR from 2024 to 2032 |
|
Segments covered |
|
|
Regional scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
In today’s hyper-connected world, running a business around the clock is no longer an option. And at Polaris Market Research, we get that. Our sales & analyst team is available 24x5 to assist you. Get all your queries and questions answered about the Benzodiazepine Drugs Market report with a phone call or email, as and when needed.
Browse Our Top Selling Reports
Center Stack Display Market Size, Share 2024 Research Report
Decarbonization Market Size, Share 2024 Research Report
Grinding Fluids Market Size, Share 2024 Research Report
Term Insurance Market Size, Share 2024 Research Report
Abrasive Blasting Nozzle Market Size, Share 2024 Research Report
© 2024 Polaris Market Research and Consulting. All rights reserved
